186 related articles for article (PubMed ID: 21360249)
1. Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection.
Maithel SK; Coban I; Kneuertz PJ; Kooby DA; El-Rayes BF; Kauh JS; Sarmiento J; Staley CA; Volkan Adsay N
Ann Surg Oncol; 2011 Sep; 18(9):2699-705. PubMed ID: 21360249
[TBL] [Abstract][Full Text] [Related]
2. An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment.
Fisher SB; Patel SH; Bagci P; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Maithel SK
Cancer; 2013 Jan; 119(2):445-53. PubMed ID: 22569992
[TBL] [Abstract][Full Text] [Related]
3. Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial.
Postlewait LM; Ethun CG; Kooby DA; Sarmiento JM; Chen Z; Staley CA; Brutcher E; Adsay V; El-Rayes B; Maithel SK
J Surg Oncol; 2016 Sep; 114(3):336-41. PubMed ID: 27501338
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
You DD; Lee HG; Heo JS; Choi SH; Choi DW
J Gastrointest Surg; 2009 Sep; 13(9):1699-706. PubMed ID: 19582512
[TBL] [Abstract][Full Text] [Related]
5. Predictive and prognostic values of ERCC1 and XRCC1 in biliary tract cancers.
Mian M; McNamara MG; Doherty M; Hedley D; Knox JJ; Serra S
J Clin Pathol; 2016 Aug; 69(8):695-701. PubMed ID: 26763622
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review.
Kim ST; Lee J; Park SH; Lee JK; Lee KT; Lee KH; Heo JS; Choi SH; Choi DW; Park YS; Lim HY; Kang WK; Jang KT; Park HC; Lim DH; Park JO
Am J Clin Oncol; 2012 Oct; 35(5):432-8. PubMed ID: 21606820
[TBL] [Abstract][Full Text] [Related]
7. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.
Li P; Fang YJ; Li F; Ou QJ; Chen G; Ma G
Br J Cancer; 2013 Apr; 108(6):1238-44. PubMed ID: 23481186
[TBL] [Abstract][Full Text] [Related]
8. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
Regine WF; Winter KA; Abrams R; Safran H; Hoffman JP; Konski A; Benson AB; Macdonald JS; Rich TA; Willett CG
Ann Surg Oncol; 2011 May; 18(5):1319-26. PubMed ID: 21499862
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
10. Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?
Valsecchi ME; Holdbrook T; Leiby BE; Pequignot E; Littman SJ; Yeo CJ; Brody JR; Witkiewicz AK
BMC Cancer; 2012 Mar; 12():104. PubMed ID: 22436573
[TBL] [Abstract][Full Text] [Related]
11. Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma.
Squires MH; Fisher SB; Fisher KE; Patel SH; Kooby DA; El-Rayes BF; Staley CA; Farris AB; Maithel SK
Cancer; 2013 Sep; 119(17):3242-50. PubMed ID: 23719746
[TBL] [Abstract][Full Text] [Related]
12. Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer.
Yan D; Wei P; An G; Chen W
J Cardiothorac Surg; 2013 Jun; 8():149. PubMed ID: 23759026
[TBL] [Abstract][Full Text] [Related]
13. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
Hwang IG; Ahn MJ; Park BB; Ahn YC; Han J; Lee S; Kim J; Shim YM; Ahn JS; Park K
Cancer; 2008 Sep; 113(6):1379-86. PubMed ID: 18623378
[TBL] [Abstract][Full Text] [Related]
14. ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
Ozdemir O; Ozdemir P; Veral A; Uluer H; Ozhan MH
Asian Pac J Cancer Prev; 2013; 14(8):4679-83. PubMed ID: 24083725
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.
Hsu CC; Herman JM; Corsini MM; Winter JM; Callister MD; Haddock MG; Cameron JL; Pawlik TM; Schulick RD; Wolfgang CL; Laheru DA; Farnell MB; Swartz MJ; Gunderson LL; Miller RC
Ann Surg Oncol; 2010 Apr; 17(4):981-90. PubMed ID: 20087786
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
Breslin TM; Hess KR; Harbison DB; Jean ME; Cleary KR; Dackiw AP; Wolff RA; Abbruzzese JL; Janjan NA; Crane CH; Vauthey JN; Lee JE; Pisters PW; Evans DB
Ann Surg Oncol; 2001 Mar; 8(2):123-32. PubMed ID: 11258776
[TBL] [Abstract][Full Text] [Related]
17. Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy.
Zhang YY; Gu KS; Wu HY; Yang F; Bu LJ; Zhao CC; Zhang YR
Genet Mol Res; 2015 Dec; 14(4):15921-9. PubMed ID: 26662383
[TBL] [Abstract][Full Text] [Related]
18. Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.
Fisher SB; Fisher KE; Patel SH; Lim MG; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Farris AB; Maithel SK
Cancer; 2013 Jan; 119(2):454-62. PubMed ID: 22760605
[TBL] [Abstract][Full Text] [Related]
19. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial.
Jones RP; Psarelli EE; Jackson R; Ghaneh P; Halloran CM; Palmer DH; Campbell F; Valle JW; Faluyi O; O'Reilly DA; Cunningham D; Wadsley J; Darby S; Meyer T; Gillmore R; Anthoney A; Lind P; Glimelius B; Falk S; Izbicki JR; Middleton GW; Cummins S; Ross PJ; Wasan H; McDonald A; Crosby T; Ting Y; Patel K; Sherriff D; Soomal R; Borg D; Sothi S; Hammel P; Lerch MM; Mayerle J; Tjaden C; Strobel O; Hackert T; Büchler MW; Neoptolemos JP;
JAMA Surg; 2019 Nov; 154(11):1038-1048. PubMed ID: 31483448
[TBL] [Abstract][Full Text] [Related]
20. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial.
Vilmar AC; Santoni-Rugiu E; Sørensen JB
Ann Oncol; 2010 Sep; 21(9):1817-1824. PubMed ID: 20332140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
